Anxiously awaited news regarding Avastin data from a Phase III study in breast cancer broke Tuesday, and - although many analysts had predicted mixed results at best - investors' faith in Genentech Inc.'s drug may have developed a few cracks. (Bioworld Today)
Friday's quick, unanimous verdict favoring Genentech Inc. in the patent case filed by Chiron Corp. concerning the former's breast cancer drug Herceptin (trastuzumab) doesn't mean the case is closed. Hardly. (Bioworld Today)
The climate may cool with September's advent, but the industry late last week was still expecting a blast of potentially hot autumnal news about Phase III trials of Genentech Inc.'s monoclonal antibody Avastin (bevacizumab) in combination with chemotherapy against breast cancer. (Bioworld Financial Watch)
In a time when funding can be as elusive as the ivory-billed woodpecker, Cellomics Inc. came up with a $15 million round of financing led by one of its earliest corporate friends: Carl Zeiss Jena GmbH, a maker of precision optics. (Bioworld Today)
On the brink of the Labor Day holiday, Genelabs Technologies Inc. saw gratifying results from the sometimes-uphill labor on behalf of its lupus drug, Prestara (prasterone), as the company's stock more than doubled on news of an approvable letter from the FDA. (Bioworld Today)
Talk to enough buy-side analysts and industry boosters, and you're likely to come away with a strangely weary feeling. It's a feeling behind which lies suspicion and skepticism, a grave doubt about even the possibility of optimism. (Bioworld Financial Watch)
